For BioNTech, ASCO Data Alone Aren’t Enough to Offset a 35% Revenue Drop and a CEO Departure

Despite encouraging oncology results at ASCO, BioNTech shares slid nearly 7% as revenue plunged 35%, co-founders announced departure, and US tariff threats loom. Stock near 52-week low.

Investors handed BioNTech a stark verdict last week: strong clinical data are no longer enough to lift the stock. The German biotech closed at €76.65 on Friday, down nearly 7% for the week, despite presenting encouraging results from its late-stage oncology pipeline at the American Society of Clinical Oncology (ASCO) meeting. The gap between scientific progress and market sentiment has rarely been wider.

At first glance, the slide looks harsh. Pumitamig, developed with Bristol Myers Squibb, showed promising anti-tumour activity in a Phase 2/3 study for first-line non-small cell lung cancer. Gotistobart delivered durable responses in heavily pre-treated ovarian cancer patients. BioNTech used the conference to spotlight a slate of late-stage assets, underscoring that its post-pandemic identity is now firmly rooted in oncology. Yet the stock sits more than 27% below its January high of €105.80, and just 12% above its 52-week low of €68.35.

The market’s scepticism is not unreasonable. BioNTech’s first-quarter numbers painted a stark financial picture: revenue dropped 35% year-on-year to €118.1 million, while the net loss ballooned to €531.9 million. For the full year, management guided for revenue of €2.0–2.3 billion, down from nearly €2.9 billion in 2025 and below consensus expectations. A company burning cash as its legacy Covid franchise shrinks cannot expect investors to pay up for Phase 2 data alone.

Adding to the pressure, the March 2026 announcement that co-founders Ugur Sahin and Özlem Türeci plan to step down by year-end sent the stock crashing 17% in a single session. Replacing visionary founders mid-pipeline build-out is a serious execution risk, and the market has yet to price it in fully. On top of that, the proposed US drug tariffs of up to 100% hang over the entire sector, making the regulatory backdrop a further headwind for biotech valuations.

Technically, the chart looks bruised. The stock trades below its 50-day moving average of €81.07 and well beneath the 200-day line. The relative strength index of 40.9 signals mounting downside pressure without a clear reversal pattern. Still, the shares have not collapsed completely: they hover some twelve per cent above the year’s low, suggesting the bears have not taken full control. The first resistance sits around the 50-day average, with a thicker zone near €86 where longer-term trend lines converge. On the downside, the 52-week low of €68.35 serves as the last meaningful support.

Analyst opinion remains split, a natural state for a company in transition. Bernstein reaffirmed a neutral stance after ASCO, voicing concerns about the clinical development plan for pumitamig. Jefferies, by contrast, kept a positive rating. The average price target of €106.32 implies a 38% upside from current levels, pointing to a broad belief that the stock is undervalued — but only if BioNTech can convert its promising pipeline into regulatory milestones.

The bull case rests on capital strength and a robust catalyst calendar. BioNTech confirmed its full-year guidance and highlighted a solid financial position, funding its oncology pivot from internal resources. It plans to launch six additional Phase 3 trials in 2026, bringing the total to 15, with seven late-stage data readouts expected. That is a heavy load of potential catalysts, but each one carries the risk of failure.

The credibility gap is clear. Investors are no longer willing to pay for aspiration; they want proof that pumitamig, gotistobart and the rest can clear the high bar of regulatory approval and commercial viability. BioNTech’s science is compelling, its pipeline deep and its balance sheet strong enough to ride out the losses. But until the company shows that its oncology investments can translate into revenue — and finds a credible leadership succession plan — the stock will remain trapped between hope and hard numbers. The opportunity is real, but it requires patience that the market, for now, is in short supply of.